Champions Oncology, Inc. (CSBR)
NASDAQ: CSBR · Real-Time Price · USD
10.17
-0.32 (-3.05%)
Feb 21, 2025, 4:00 PM EST - Market closed
Champions Oncology Revenue
Champions Oncology had revenue of $13.49M in the quarter ending October 31, 2024, with 16.56% growth. This brings the company's revenue in the last twelve months to $53.57M, up 7.19% year-over-year. In the fiscal year ending April 30, 2024, Champions Oncology had annual revenue of $50.16M, down -6.90%.
Revenue (ttm)
$53.57M
Revenue Growth
+7.19%
P/S Ratio
2.58
Revenue / Employee
$255,100
Employees
210
Market Cap
139.32M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Apr 30, 2024 | 50.16M | -3.72M | -6.90% |
Apr 30, 2023 | 53.87M | 4.76M | 9.69% |
Apr 30, 2022 | 49.11M | 8.07M | 19.66% |
Apr 30, 2021 | 41.04M | 8.92M | 27.76% |
Apr 30, 2020 | 32.12M | 5.06M | 18.68% |
Apr 30, 2019 | Pro | Pro | Pro |
Apr 30, 2018 | Pro | Pro | Pro |
Apr 30, 2017 | Pro | Pro | Pro |
Apr 30, 2016 | Pro | Pro | Pro |
Apr 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CSBR News
- 4 days ago - Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting - Accesswire
- 6 weeks ago - Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership - Accesswire
- 2 months ago - Champions Oncology: Right Point To Own In The Cycle Thanks To Operating Efficiencies - Seeking Alpha
- 2 months ago - Champions Oncology, Inc. (CSBR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million - Accesswire
- 2 months ago - Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024 - Accesswire
- 4 months ago - Champions Oncology Announces Agreement with Weill Cornell Medicine - Accesswire
- 5 months ago - Champions Oncology, Inc. (CSBR) Q1 2025 Earnings Call Transcript - Seeking Alpha